Results 171 to 180 of about 1,811,188 (293)

Outbreak and dissemination of the international high-risk NDM-5-producing <i>Escherichia coli</i> ST410 clone in companion animal hospitals in China. [PDF]

Zool Res
Cai ZP, Zhu BQ, Liu WH, Hou JQ, Wen XE, He WY, Xiao LD, Tu JY, Wu ZW, Liu JH, Lv LC.   +10 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Current Status and Barriers of Ophthalmic Examination Services in Companion Animal Clinics in South Korea. [PDF]

Vet Med Int
Kim JW, Kim HYS, Kim K.
europepmc   +1 more source

The Regulation of Companion Animal Services in Relation to Training and Behaviour Modification of Dogs

, 2008
Companion Animal Welfare Council, McBride, E.A.   +1 more
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Editorial: Emerging challenges in companion animal toxicology. [PDF]

Front Vet Sci
Bates N, Hovda LR, Seljetun KO.
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Correction: Editorial: Endocrine disruptors affecting human and companion animal endocrine function: similarities and indicators in the one health concept - volume II. [PDF]

Front Endocrinol (Lausanne)
Frontiers Production Office.
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

A structured, behavioural science approach to the preparation of antimicrobial stewardship interventions for companion animal veterinarians. [PDF]

Vet Rec
Walker B, O'Neill D, Stacey H, Brodbelt D.   +3 more
europepmc   +1 more source